GlobalData on MSN5d
Palleon and Shanghai Henlius Biotech link on autoimmune therapy
Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered a licence agreement and partnership for the former’s ...
Business Insider3d
Shanghai Henlius Biotech to Vote on Major Merger
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter ...
Hosted on MSN3d
Shanghai Fosun Pharmaceutical Advances Henlius Merger Plans
Shanghai Fosun Pharmaceutical is moving forward with the proposed privatization of Shanghai Henlius Biotech through a merger by absorption. The company has dispatched a composite ...
Business Insider3d
Shanghai Henlius Biotech Moves Toward Privatization
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter ...
Shanghai Henlius Biotech shares soar in Hong Kong after Fosun’s US$690 million buyout offer
Hong Kong-listed Shanghai Henlius Biotech surged 18.9 per cent to a two-year high after drug maker Fosun Pharma offered ...
TipRanks on MSN21d
Shanghai Henlius Biotech’s Biosimilar Gains Regulatory Nod
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Shanghai Henlius Biotech, Inc. has achieved a significant milestone with ...
Nature3y
Henlius: using a fully integrated platform to advance high-quality, affordable biologics
Shanghai Henlius Biotech, Inc. has progressed quickly since it began operating in 2010. Today, Henlius is a fully integrated biopharmaceutical company with dozens of clinical-phase candidates ...
Nasdaq21d
Shanghai Henlius Biotech Advances in HER2 Therapy Trial
Shanghai Henlius Biotech, Inc. has received approval from the National Medical Products Administration for a phase 2 clinical trial of its innovative anti-HER2 monoclonal antibody, HLX22 ...
Nasdaq21d
Shanghai Henlius Biotech Plans Key Shareholder Meeting
Shanghai Henlius Biotech, Inc. is set to hold an extraordinary general meeting in December to discuss and potentially approve key agreements vital to the company’s strategic plans. Shareholders ...
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced a collaboration and license agreement with Shanghai Henlius ...
High Growth Tech Stocks Including Shanghai Henlius Biotech
As global markets experience fluctuations with major indexes like the Nasdaq Composite reaching new highs, small-cap stocks face challenges as evidenced by the Russell 2000's recent underperformance.
Shanghai Henlius Biotech Announces Merger Vote
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended ...